Fuzhou Aging Brain Health Initiative--Health Aging and Alzheimer's Disease Cohort and Early Diagnosis and Treatment Research
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China. The primary purposes are as follows: 1. establishment and follow-up of cohorts in the general population and populations with cognitive impairment; 2. investigation of risk factors and evolutionary patterns of AD pathological characteristics; 3. construction and validation of AD digital phenotypes based on multi-dimensional digital-intelligence screening; 4. exploration of AD-related risk genes and their mechanisms of action; 5. development of novel technologies for plasma biomarkers and PET imaging for the accurate diagnosis of AD.
• Age between 55 and 90 years, both sexes eligible;
• Educational level of primary school or above, or with a sound working history, excluding individuals with intellectual disability;
• Able to speak Mandarin fluently and capable of completing the full battery of neuropsychological assessments;
• Geriatric Depression Scale (GDS) score ≤ 6;
• Adequate visual and auditory function to complete all neuropsychological tests successfully;
• Willing and able to provide peripheral blood samples and to undergo brain PET and MRI neuroimaging examinations;
• If taking relevant medications, the dosage must have been stable for at least 4 weeks. Specific medication requirements: stable doses of antidepressants are permitted, provided that the participant has no significant anticholinergic adverse effects and no history of major depressive episode within the past year; estrogen replacement therapy is allowed; Ginkgo biloba preparations may be taken, but routine use is not recommended; use of any psychoactive drugs is prohibited within 4 weeks prior to screening.